{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"}],"units":"Participants"}],"groups":[{"description":"Single dose of 1-3x10\\^7 huCARTmeso cells/m\\^2\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG000","title":"Cohort 1"},{"description":"Cyclophosphamide 1 gram/m\\^2 administered 2-4 days prior to a single dose of 1-3x10\\^7 huCARTmeso cells/m\\^2\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG001","title":"Cohort 2"},{"description":"PERMANENTLY CLOSED\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG002","title":"Cohort 3"},{"description":"PERMANENTLY CLOSED\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG003","title":"Cohort 4"},{"description":"Single dose of 1-3x10\\^7 huCART-meso cells/m\\^2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG004","title":"Cohort 5"},{"description":"Cyclophosphamide 1 gram/m\\^2 administered 2-4 days prior to dose of 1-3x10\\^7 huCART-meso cells/m\\^2 via IV infusion on Day 0. This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG005","title":"Cohort 6"},{"description":"Cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day given over 3 days by IV infusion followed by a single dose of 1-3x10\\^7 huCART-meso cells/m\\^2 via intraperitoneal (i.p.) administration. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG006","title":"Cohort 7"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cohort 4 closed prematurely.","reportingStatus":"POSTED","timeFrame":"7 years","title":"Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03","type":"PRIMARY","unitOfMeasure":"Participants"}